The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
teva reports strong generics demand raises 2024 revenue outlook
Teva Pharmaceuticals reported a 13% revenue increase in Q3, reaching $4.3 billion, driven by strong demand for its generics, particularly in the U.S. The company raised its full-year revenue guidance to $16.1-$16.5 billion, bolstered by successful products like Austedo and upcoming biosimilars, including Selarsdi and Simlandi. CEO Richard Francis emphasized a renewed focus on growth strategies to sustain this momentum.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.